Lumen Bioscience a Seattle-based clinical-stage biotechnology company, announced on Thursday that it has received a new USD8.8m project funded by the US Department of Defense (DOD) for the development and testing of a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of known and emerging viral respiratory infections.
The contract was awarded by the Defense Innovation Unit (DIU) under its 'Project Panacea' and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), under its Vaccine Acceleration by Modular Progression program.
The funding will support development and testing of intranasal host-directed therapeutic using Lumen's low-cost, highly scalable cGMP production platform and novel formulation technology. The therapeutic is a human immune signalling protein known to be especially important in the body's immune response to respiratory viral infections like influenza. Human clinical trials by other groups have shown that the therapeutic, when injected, was safe and effective against COVID-19 and other diseases. Animal experiments by other researchers show that intranasal dosing may be a safe and effective approach for both treating and preventing influenza and COVID-19. The new Lumen project unites these two lines of research, as well as testing other CBRN threats of interest. The project is intended to yield a prototype shelf-stable, inexpensive, self-administered product candidate ready for human trials.
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract